Navigation Links
Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
Date:9/26/2013

INDIANAPOLIS, Sept. 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from two global Phase III studies of ramucirumab (IMC-1121B), one in advanced gastric cancer and another in metastatic breast cancer.

The RAINBOW trial, a global Phase III study of ramucirumab in combination with paclitaxel in patients with advanced gastric cancer, met its primary endpoint of improved overall survival and a secondary endpoint of improved progression-free survival.

The global, randomized, double-blind RAINBOW trial compared ramucirumab and paclitaxel to placebo and paclitaxel in patients with advanced (locally advanced, unresectable or metastatic) gastric cancer that was refractory to or progressive after initial chemotherapy. The most common (>5% incidence) Grade >3 adverse events occurring at a higher rate on the ramucirumab-plus-paclitaxel arm compared to the control arm included neutropenia, leukopenia, hypertension, fatigue/asthenia and abdominal pain.

"We are excited to see a second positive Phase III trial of ramucirumab in gastric cancer demonstrating an improvement in both overall survival and progression-free survival, as stomach cancer is a difficult-to-treat disease that remains a major health problem worldwide and the prognosis for patients diagnosed with advanced gastric cancer is poor," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. 

The first positive study, REGARD, showed single-agent ramucirumab improved overall survival and progression-free survival in patients with advanced gastric cancer who have had disease progression after initial chemotherapy.  There are no agents specifically approved in the U.S. or EU for advanced gastric cancer patients in this setting.

Lilly plans
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Company announces the recent formation of Alamo ... wholly owned subsidiary of Mission, will provide ... resources (HR) support.  Alamo will be headquartered ... States presence, which also includes the company,s ...
... Jan. 26, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc.- Florida has reached a settlement with ... Watson,s generic versions of Mallinckrodt,s Exalgo® (Hydromorphone Hydrochloride ... December 10, 2010 in the United States District ...
Cached Medicine Technology:Mission Pharmacal Launches Alamo Pharma Services 2Mission Pharmacal Launches Alamo Pharma Services 3Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... reveals racial disparities, troublesome drug side effects , , THURSDAY, ... first annual Breast Cancer Symposium shed light on racial ... can affect survival, and how nagging side effects cause ... in San Francisco, is co-sponsored by the American Society ...
... Stars, Nation,s ... Sept. 6 Consumer,selection of foods that offer more ... don,t in many aisles of Hannaford Supermarkets --,in some ... data in the year,since the company launched Guiding Stars, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced that ... Food and Drug Administration for its,Abbreviated New Drug Application ... and 25 mg. Carvedilol Tablets are the generic ... of approximately $1.65,billion for the 12 months ending June ...
... N.Y., Sept. 5 Fairbank Farms, a national,ground ... Lean Ground Round Beef Patties. The ground beef ... been purchased by consumers in New,England on Wednesday ... of an abundance of caution, the product has ...
... starved environments have been used successfully to target ... according to scientists speaking today (Thursday 6 September ... Meeting at the University of Edinburgh, UK, which ... half of cancer sufferers our traditional treatments such ...
... Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... the product will commence,immediately. Carvedilol tablets, ... be available in 3.125, 6.25, 12.5 and ...
Cached Medicine News:Health News:Studies Shed New Light on Breast Cancer, Treatment 2Health News:Studies Shed New Light on Breast Cancer, Treatment 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bacteria successful in cancer treatment 2Health News:Actavis Launches Carvedilol Tablets in the U.S. 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Acuity Meter (RAM) is the first visual examination ... RETINAL ACUITY in eyes with glaucoma, cataract, and ... and can test each eye easily in under ... tested at Columbia University in New York City, ...
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
... Ace Align is an external fixator designed ... of the femur, tibia, humerus and forearm. ... where external fixation is the treatment of ... ,The Ace Align is fully compatible with ...
Medicine Products: